1-(2-Chloro-4-nitrophenyl)piperazine - CAS 114878-60-3
Catalog: |
BB003445 |
Product Name: |
1-(2-Chloro-4-nitrophenyl)piperazine |
CAS: |
114878-60-3 |
Synonyms: |
1-(2-chloro-4-nitrophenyl)piperazine; 1-(2-chloro-4-nitrophenyl)piperazine |
IUPAC Name: | 1-(2-chloro-4-nitrophenyl)piperazine |
Description: | 1-(2-Chloro-4-nitrophenyl)piperazine (CAS# 114878-60-3) is a useful research chemical. |
Molecular Weight: | 241.67 |
Molecular Formula: | C10H12ClN3O2 |
Canonical SMILES: | C1CN(CCN1)C2=C(C=C(C=C2)[N+](=O)[O-])Cl |
InChI: | InChI=1S/C10H12ClN3O2/c11-9-7-8(14(15)16)1-2-10(9)13-5-3-12-4-6-13/h1-2,7,12H,3-6H2 |
InChI Key: | JNUWBYPJOBSXDN-UHFFFAOYSA-N |
Boiling Point: | 411 °C at 760 mmHg |
Density: | 1.331 g/cm3 |
Appearance: | Solid |
Storage: | Keep in dark place, Sealed in dry, Room Temperature |
MDL: | MFCD00640776 |
LogP: | 2.57480 |
GHS Hazard Statement: | H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]; H312 (100%): Harmful in contact with skin [Warning Acute toxicity, dermal]; H332 (100%): Harmful if inhaled [Warning Acute toxicity, inhalation] |
Precautionary Statement: | P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501 |
Signal Word: | Warning |
Publication Number | Title | Priority Date |
KR-101653560-B1 | Novel compound or pharmaceutically acceptable salt thereof and pharmaceutical composition for prevention or treatment of disease caused by influenza virus infection containing the same as an active ingredient | 20160202 |
KR-20160021163-A | Novel compound or pharmaceutically acceptable salt thereof and pharmaceutical composition for prevention or treatment of disease caused by influenza virus infection containing the same as an active ingredient | 20160202 |
KR-101717601-B1 | Novel compound or pharmaceutically acceptable salt thereof and pharmaceutical composition for prevention or treatment of disease caused by influenza virus infection containing the same as an active ingredient | 20151110 |
KR-20150134301-A | Novel compound or pharmaceutically acceptable salt thereof and pharmaceutical composition for prevention or treatment of disease caused by influenza virus infection containing the same as an active ingredient | 20151110 |
CN-103435553-A | Piperazine structure-based aryl formamide Raf kinase inhibitor and preparation method as well as application thereof | 20130916 |
PMID | Publication Date | Title | Journal |
20508873 | 20100501 | Gateways to clinical trials | Methods and findings in experimental and clinical pharmacology |
Complexity: | 253 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 241.0618043 |
Formal Charge: | 0 |
Heavy Atom Count: | 16 |
Hydrogen Bond Acceptor Count: | 4 |
Hydrogen Bond Donor Count: | 1 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 241.0618043 |
Rotatable Bond Count: | 1 |
Topological Polar Surface Area: | 61.1 |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 1.8 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Piperazines
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS